GlassScriptPhysician profile
Mark S Brigham
NPI 1740261387
$2,937.66
in general payments reported to CMS, 2019-2025
20 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $110 · 2021: $271 · 2022: $441 · 2023: $590 · 2024: $405 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592 · Education: $73.72 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.86 |
| Education | $73.72 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $571.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $508.85 | 2020-2025 | Dupixent |
| Optinose US, INC. | $406.02 | 2019-2025 | |
| Inspire Medical Systems, INC. | $382.93 | 2023-2025 | Inspire |
| Stryker Corporation | $220.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $172.21 | 2021-2025 | Nucala |
| Intersect Ent, INC. | $121.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.02 | 2021-2025 | Fasenra, Tezspire |
| Integra Lifesciences Corporation | $83.56 | 2021-2022 | |
| Acclarent, INC | $58.12 | 2019 | |
| Paratek Pharmaceuticals, INC. | $55.50 | 2025 | Xhance |
| Sanofi-Aventis U.S. LLC | $45.56 | 2022 | |
| Lucid Diagnostics INC. | $37.14 | 2023 | |
| Smith+Nephew, INC. | $35.38 | 2020-2024 | Coblation |
| Medtronic, INC. | $35.00 | 2023 | Merocel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.50 | 2019-2021 | |
| Abbvie INC. | $20.44 | 2023 | Botox |
| Aerin Medical INC. | $17.93 | 2023 | |
| Merck Sharp & Dohme LLC | $15.60 | 2023 | |
| Hikma Pharmaceuticals USA | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.